Alzamend Neuro Inc (NASDAQ: ALZN) has submitted an investigational new drug (IND) application to the FDA to initiate AL001-BD01, a Phase 2A study of AL001 for bipolar disorder.
Lithium is a commonly prescribed drug for manic episodes in bipolar disorder type 1 and maintenance therapy for bipolar disorder in patients with a history of manic episodes.
AL001 is a novel lithium-delivery system that can potentially deliver the benefits of marketed lithium salts while mitigating or avoiding currently experienced toxicities associated with lithium.
Alzamend tells Benzinga that lithium carbonate ...